drugset / Trial / NCT02911324
Cannabinoid Medication for Adults With OCD
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this pilot research study is to test the effects of a medication called nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will receive either nabilone on its own, or nabilone in combination with a form of cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.
Timeline
- Start
- 2016-09
- Primary completion
- 2019-01
- Completion
- 2019-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nabilone | Other / unclassified | 1 mg | — |